BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Muller M, D'Amico F, Bonovas S, Danese S, Peyrin-Biroulet L. TNF Inhibitors and Risk of Malignancy in Patients with Inflammatory Bowel Diseases: A Systematic Review. J Crohns Colitis 2021;15:840-59. [PMID: 32915970 DOI: 10.1093/ecco-jcc/jjaa186] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu R, Wan Q, Zhao R, Xiao H, Cen Y, Xu X. Risk of non-melanoma skin cancer with biological therapy in common inflammatory diseases: a systemic review and meta-analysis. Cancer Cell Int 2021;21:614. [PMID: 34809619 DOI: 10.1186/s12935-021-02325-9] [Reference Citation Analysis]
2 Miao Z, Gu M, Yan J, Lu L, Xu Y, Ning L, Xu Y. Dual-targeted colon-based integrated micelle drug delivery system for treatment of ulcerative colitis. Journal of Drug Targeting. [DOI: 10.1080/1061186x.2022.2052887] [Reference Citation Analysis]
3 Singh S, Proctor D, Scott FI, Falck-Ytter Y, Feuerstein JD. AGA Technical Review on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021;160:2512-2556.e9. [PMID: 34051985 DOI: 10.1053/j.gastro.2021.04.023] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Singh S, Heien HC, Sangaralingham L, Shah ND, Sandborn WJ. Risk of Malignancy with Vedolizumab Versus Tumor Necrosis Factor-α Antagonists in Patients with Inflammatory Bowel Diseases. Dig Dis Sci 2021. [PMID: 34085174 DOI: 10.1007/s10620-021-07073-4] [Reference Citation Analysis]
5 Mahapatro M, Erkert L, Becker C. Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut. Cells 2021;10:111. [PMID: 33435303 DOI: 10.3390/cells10010111] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]